Neuroendocrine Tumor Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Neuroendocrine Tumor stocks.

Neuroendocrine Tumor Stocks Recent News

Date Stock Title
May 10 CRNX Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10 CRNX Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results
May 9 CRNX Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
May 9 AQST Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript
May 9 CRNX Crinetics Pharmaceuticals GAAP EPS of -$0.93 misses by $0.13, revenue of $0.6M beats by $0.42M
May 9 CRNX Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 9 AQST Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
May 9 AQST Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 9 AQST Aquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
May 8 CRNX Crinetics Pharmaceuticals Q1 2024 Earnings Preview
May 8 CRNX Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
May 8 AQST Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript
May 8 AQST Aquestive Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
May 7 AQST Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
May 7 AQST Aquestive Therapeutics GAAP EPS of -$0.17, revenue of $12.05M
May 7 AQST Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
May 7 AQST Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 6 AQST Aquestive Therapeutics Q1 2024 Earnings Preview
May 6 AQST Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
Neuroendocrine Tumor

A neuroendocrine tumor (NET) is a type of cancer that develops from cells of the neuroendocrine system. This system is made up of cells that release hormones in response to signals from the nervous system. Neuroendocrine tumors can occur anywhere in the body and can be benign (non-cancerous) or malignant (cancerous). Symptoms of NETs vary depending on the location and type of tumor, but may include abdominal pain, diarrhea, weight loss, and fatigue. Treatment options may include surgery, chemotherapy, radiation, and targeted therapy.

Browse All Tags